How much does Delamanid cost for 6 months

Delamanid is an oral anti-tuberculosis drug for patients with multidrug-resistant tuberculosis (MDR-TB). The recommended dose for adults is 100 mg twice daily for 24 weeks, or 6 months. The drug has been approved for marketing in China and is included in the scope of Class B medical insurance, but reimbursement is limited to patients with multi-drug-resistant tuberculosis, who must meet the prescribed indications to enjoy the medical insurance policy.

The common specifications of Delamani original drug on the market are50mg*60 tablets per box. Calculated based on adult standard doses, six-month treatment usually requires multiple boxes of drugs, and the total cost is about more than 6,000 yuan. The specific amount will vary depending on regional drug price adjustments and medical insurance reimbursement ratios. Due to the long treatment period for MDR-TB, drug costs are relatively high. However, combined with the medical insurance reimbursement policy, patients' actual out-of-pocket costs can be significantly reduced.

When using delamanid to treat multidrug-resistant tuberculosis, it needs to be used in combination with other anti-tuberculosis drugs under the guidance of a doctor to enhance the efficacy and reduce the risk of drug resistance. During the entire treatment cycle, patients need to regularly monitor liver function, blood and tuberculosis indicators to ensure drug safety. At the same time, taking medications on time and following medical instructions are crucial to the success rate of treatment. Delays or missed doses may affect the effectiveness of treatment and increase the risk of drug resistance.

Globally, delamanid has also received widespread attention due to its targeted effect and good tolerability, and has become an important part of the MDR-TB treatment plan in many countries. Its relatively stable drug prices and medical insurance support allow patients to control their economic burden while receiving standard treatment, which helps improve treatment coverage and compliance for multi-drug-resistant tuberculosis.

In short, the cost of 6 months of treatment with Dramani is approximately more than RMB 6,000. With the support of medical insurance, patients can obtain affordable treatment options. Rational use of delamanid can not only effectively control multi-drug-resistant tuberculosis, but also reduce the recurrence rate and risk of transmission, providing guarantee for public health prevention and control.

Reference: https://go.drugbank.com/drugs/DB11637